

Xenon Pharmaceuticals Inc

[View the current Xenon Pharmaceuticals Inc Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/32137-Xenon+Pharmaceuticals+Inc.html)

(<http://www.bioportfolio.com/bi corporate/32137-Xenon+Pharmaceuticals+Inc.html>)

Contact Details:

**3650 Gilmore Way
Burnaby
British Columbia
V5G 4W8
Canada**

Tel: 604.484.3300
Fax: 604.484.3450
Email: info@xenon-pharma.com

Xenon is a privately held company located in Vancouver and has just over 70 employees. We are a leader in clinical genetic based drug discovery and development and have built a worldwide network of over 40 clinical collaborators to find and access the rare families with diseases of relevance to drug discovery. Our clinical genetic approaches are:

Extreme Genetics TM: the analysis of rare families that have multiple cases of a severe (extreme) clinical picture of a common disease with unmet medical need.

Opposite Phenotype: the analysis of rare genetic disorders, which have the opposite clinical features to a common disease.

Genetically Modified Models: Xenon creates novel in vivo models representative of human disease through utilizing loss-of-function (knockout) and over-expression (transgenic) strategies.

Recent Publications by Xenon Pharmaceuticals Inc:



- [Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations.](#)
*Congenital indifference to pain (CIP) is a rare condition in which...*22nd June, 2007
Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G4W8, Canada.- Clin Genet. 2007 Apr;71(4):311-9. ([DOI Direct Link](#))
- [Dopamine D1-like receptor modulates layer- and frequency-specific short-term synaptic plasticity in rat prefrontal cortical neurons.](#)
*The mesocortical dopamine (DA) input to the prefrontal cortex (PFC) is...*15th September, 2005
Drug Discovery, Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC,- Eur J Neurosci. 2005 Jun;21(12):3310-20. ([DOI Direct Link](#))

Press Releases on Xenon Pharmaceuticals Inc:

Onyx Pharmaceuticals Announces December 2009 Investor Events	25th November, 2009	Onyx Pharmaceuticals, Inc.	EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7,
Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference	25th November, 2009	Ardea Biosciences, Inc.	SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper
iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering	25th November, 2009		DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals' service division and Pyxis Discovery announced today that they have signed a collaborative agreement
Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective http://www
Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Intranasal Drug Delivery - US Market Trends & Analysis http://www



Xenon Pharmaceuticals Inc Patents:

- 7605161- [Pyridyl derivatives and their use as therapeutic agents](#)
- 7232662- [Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5](#)
- 7294480- [High throughput screening assays using fatty acid synthetic enzymes](#)
- 7297523- [Human elongase genes and uses thereof](#)
- 7335658- [Pyridazine derivatives and their use as therapeutic agents](#)
- 7390813- [Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents](#)
- 7435559- [Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5](#)
- 7456180- [Piperazine derivatives and their use as therapeutic agents](#)
- 7511018- [Juvenile hemochromatosis gene \(HFE2A\) cleavage products and uses thereof](#)
- 7514436- [Pyridazine derivatives and their use as therapeutic agents](#)
- 7534764- [Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin](#)
- 7547698- [Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase \(SCD\)](#)
- 7592343- [Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors](#)
- 6987001- [Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

